Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019

Background: Coronavirus disease 2019 (COVID-19) is a novel disease associated with a cytokine-mediated, severe, acute respiratory syndrome. Tocilizumab and lenzilumab are recombinant monoclonal antibodies against IL-6 and granulocyte macrophage colony-stimulating factor, respectively, and have been...

Descripción completa

Detalles Bibliográficos
Autores principales: Melody, Megan, Nelson, Jared, Hastings, Jacquelyn, Propst, Joshua, Smerina, Michael, Mendez, Julio, Guru, Pramod
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319491/
https://www.ncbi.nlm.nih.gov/pubmed/32546029
http://dx.doi.org/10.2217/imt-2020-0136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319491/
https://www.ncbi.nlm.nih.gov/pubmed/32546029
http://dx.doi.org/10.2217/imt-2020-0136

Ejemplares similares